Double immunostainings with antibodies against β-gal and neuronal (NeuN), astrocytic (GFAP) or microglial (CD11b) markers identified the presence of the EphA4/β-gal fusion protein in neurons at 2 weeks (Fig. 1A) and 3 weeks (Fig. 1B) after experimental stroke in EphA4LacZ mice. Here, RBFOX3 is linked to stroke disorder.